Evidence map›Paper›PMID 42458330›Full record

ArticleBMC cancer2026

Inhibition of the ATR-CHK1 signaling pathway sensitizes MCPyV-positive Merkel cell carcinoma to gemcitabine.

Evelyn V Proctor, Sherine F Elsawa, Sarah R Walker, Jingwei Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Merkel Cell Polyomavirus and DNA Damage Response.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Evelyn V ProctorDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, 46 College Rd, Rudman 206, Durham, NH, 03824, USA.
Sherine F ElsawaDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, 46 College Rd, Rudman 206, Durham, NH, 03824, USA.
Sarah R WalkerDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, 46 College Rd, Rudman 206, Durham, NH, 03824, USA.
Jingwei ChengDepartment of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, 46 College Rd, Rudman 206, Durham, NH, 03824, USA. jingwei.cheng@gmail.com.

Funding

TLR-TRIF mediated induction of GLI3 modulates innate inflammatory responsesP20GM113131 · NIGMS · UNIVERSITY OF NEW HAMPSHIRE · PI W Kelley THOMAS · 2017 to 2026
$22.8M
NIGMS NIH HHS P20 GM113131NIGMS NIH HHS P20GM113131
6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is the primary cutaneous neuroendocrine carcinoma with a mortality rate higher than that of melanoma and other common skin cancers. In the United States, most cases of MCC are positive for Merkel cell polyomavirus (MCPyV), in which the viral small T antigen (ST) recruits the Tip60-EP400 chromatin remodeling complex to L-Myc, a MYC family protein with oncogenic properties. This complex initiates MYC-dependent transcriptional programs that induce replication stress. Given that ATR-CHK1 is crucial for responding to replication stress and maintaining genomic integrity, we investigated whether this ST-driven L-Myc/Tip60-EP400 program is associated with heightened reliance on ATR-CHK1 signaling in MCPyV

Indexed as

Ataxia Telangiectasia Mutated ProteinsCarcinoma, Merkel CellCheckpoint Kinase 1DeoxycytidineMerkel cell polyomavirusSkin NeoplasmsAntimetabolites, AntineoplasticCell Line, TumorCell ProliferationGemcitabineHumansSignal TransductionAntimetabolites, AntineoplasticAtaxia Telangiectasia Mutated ProteinsATR protein, humanCheckpoint Kinase 1CHEK1 protein, humanDeoxycytidineGemcitabineATRCHK1DNA damage responseGemcitabineMerkel cell carcinoma

Identifiers

PMID42458330
PMCPMC13679154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.